Journal of Cell Science & Therapy
Open Access
ISSN: 2157-7013
+44 1300 500008
ISSN: 2157-7013
+44 1300 500008
Knyazev O, Kagramanova A, Fadeeva N, Boldyreva O, Lishchinskaya A, Ruchkina I, Babayan A, Kirova M, Konoplyannikov A, Noskova K, Orlova N and Parfenov A
Moscow Clinical Research Center, Russia
Medical Radiological Research Center, Russia
Posters & Accepted Abstracts: J Cell Sci Ther
Introduction: Anticytokine therapy with anti-TNF-alpha drugs contribute to the achievement of stable remission of Crohn's Disease (CD). For the treatment of CD Mesenchymal Stromal Cells (MSCs) are also used. Objective: To examine the long-term efficacy (7 years) therapy of Mesenchymal Stromal Cells (MSCs) from the bone marrow of patients with luminal Crohn's Disease (CD). Materials & Methods: 80 patients with luminal form CD (terminal ileitis, colitis and ileokolit) were divided into two groups. The first group of patients aged 19 to 58 years old (Me-29) (n=34) received the culture of MSCs under the scheme (0-1-2-3, then every 26 weeks). The second group of patients with CD (n=46) aged 20 to 62 years (ME-28) received standard anti-inflammatory therapy with 5-aminosalicylic acid (5-ASA), glucocorticosteroids (GCS) and immunosuppressive (IS). Evaluation of the effectiveness of therapy on the level of the index of activity of Crohn's Disease (CDAI<150 point) was carried out at 12, 24, 36, 48, 60, 72 and 84 months after initiation of therapy. Results: Among the patients in 1-st group, relapse in the 12 months of observation occurred in 4/36 patients (11.76%). In 2-nd group, relapse occurred in 5/46 (10.8%) (p=0.82). After 24 months in the 1-st group of patients receiving MSC, relapse occurred in 6/34 (17.6%). In the 2-nd group of patients relapse occurred in 19/27 (41.3%) (p=0.044). After 36 months in 1-st group patients with a relapse of the disease was in 11/34 (32.3%). In the 2-nd group relapse was 29/46 (63.1%) (p=0.01). After 48 months in 1-st group, receiving MSCs, relapsed in 15/34 (44.1%). In the 2-nd group relapse was in 33/46 (71.7%) (p=0.023). After 60 months in the 1-st group relapse was in 19/34 (55.9%). In the 2-nd group relapse was 40/46 (86.9%) (p=0.004). After 72 months in 1-st group relapse was 25/34 (73.5%). In 2-nd group relapse of the CD occurred in 45/46 (97.8%) (p=0.001). After 84 months in 1-st group relapse CD occurred in 29/34 (85.3%). In the 2-nd group of patients CD relapse occurred in 46/46 (100.0%) (p=0.011). Conclusions: MSCs transplantation helps to maintain a long-term clinical remission in patients with luminal crohn's disease compared with GCS/IS therapy.
Email: oleg7@bk.ru